Clinical Study

Gender- and Age-Specific Differences in the Association of Hyperuricemia and Hypertension: A Cross-Sectional Study

Xiaoyun Lin,1 Xiqian Wang,2 Xin Li,3 Lili Song,3 Zhaowei Meng,1 Qing Yang,4 Wenjuan Zhang,4 Yuxia Gao,4 Zhenwen Yang,4 Heng Cai,4 Bo Bian,4 Yongle Li,4 Xuefang Yu,4 Xin Du,4 Shaopeng Xu,4 Jing Nie,4 Ming Liu,5 Jinhong Sun,6 Qing Zhang,6 Ying Gao,6 Kun Song,6 Xing Wang,6 Li Zhao,7 and Yaguang Fan8

1Department of Nuclear Medicine, Tianjin Medical University General Hospital, Tianjin, China
2Department of Nephrology, Tianjin Medical University General Hospital, Tianjin, China
3College of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China
4Department of Cardiology, Tianjin Medical University General Hospital, Tianjin, China
5Department of Endocrinology and Metabolism, Tianjin Medical University General Hospital, Tianjin, China
6Department of Health Management, Tianjin Medical University General Hospital, Tianjin, China
7Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, China
8Tianjin Key Laboratory of Lung Cancer Metastasis and Tumor Microenvironment, Tianjin Lung Cancer Institute, Tianjin Medical University General Hospital, Tianjin, China

Correspondence should be addressed to Zhaowei Meng; jamesmencius@163.com and Yaguang Fan; fanyaguang75@163.com

Received 20 November 2018; Accepted 21 January 2019; Published 28 February 2019

Academic Editor: Michael Horowitz

Copyright © 2019 Xiaoyun Lin et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objective. Both hyperuricemia and hypertension have important clinical implications, but their relationship in terms of gender and age is still a matter of debate. In this study, we aimed to explore gender- and age-specific differences in this association between hyperuricemia and hypertension in a Chinese population. Methods. A total of 78,596 ostensibly healthy subjects (47,781 men and 30,815 women) were recruited. The association between hyperuricemia and hypertension was analyzed by multivariate logistic regression, and the analyses were stratified by gender and age. Results. Overall prevalence of hypertension and hyperuricemia was significantly higher in males than in females. Increasing trends of hypertension prevalence in both genders as well as hyperuricemia prevalence in females were found along with aging. However, males showed a reduced trend in hyperuricemia prevalence with aging. Higher hypertension and hyperuricemia prevalence was found in young and middle-aged men than in women, but not in elderly people older than 70 years. Significantly increased risk of hypertension from hyperuricemia was found only in men with an adjusted odds ratio of 1.131 (P < 0.01), especially in the middle-aged male participants. However, such significant results were not found in women. Similarly, hyperuricemia was also an independent risk factor of increased systolic blood pressure and diastolic blood pressure in males, but not in females. Conclusion. We observed significantly higher overall prevalence of hyperuricemia and hypertension in men than in women. Men with hyperuricemia (particularly in middle age) had a significantly increased susceptibility of hypertension, while this significant association was not observed in women.

1. Introduction

Hypertension is one of the most common cardiovascular diseases and is also the leading preventable cause of premature death worldwide [1]. The global age-standardized prevalence of hypertension was estimated as 24.1% in men and 20.1% in women in 2015. Alarmingly, the number of adults with raised blood pressure increased from 594 million in 1975 to 1.13 billion in 2015, with the increase largely in low-income and middle-income countries [2].

Uric acid (UA) is generated as part of the normal turnover of nucleic acid. UA circulates in plasma predominantly
in the form of a monovalent sodium salt (urate) [3]. The possibility that UA may be associated with hypertension has been considered for more than a century [4]. However, the interest in the possible link between hypertension and UA waxed and waned during much of the 20th century [5]. It was not until 2001 that a rat model was established to show that the increases in blood pressure were proportional to hyperuricemia induced by providing a uricase inhibitor (oxonic acid) in the diet, which could be ameliorated by UA-lowering drugs [6].

Hyperuricemia has also become a hot topic in recent years [7–9]. However, the opinion on the relationship between hypertension and hyperuricemia is not unanimously accepted as the abovementioned rat model experiment. For instance, several randomized trials have failed to show such a relationship [10, 11]. Palmer et al. [10] argued that body mass index (BMI) could be an important confounder in the development of UA-related conditions rather than UA per se. Some studies also failed to demonstrate that UA-lowering agents could affect endothelial function [11] or the renin-angiotensin system activity [12], both of which were potential mechanisms for the development of hypertension. Another obvious controversy is about the gender- and age-specific differences. Some studies found a more pronounced risk of hypertension associated with hyperuricemia in females [13–15], some in males [16–19], while others in both genders [20, 21]. The age-related variance was even more debated. Lee et al. [22] showed that only people younger than 40 years had significant associations between UA and hypertension, while studies from Yoki et al. [23] and Cheng et al. [24] demonstrated that only participants older than 40 years had such a relationship. Interestingly, in a Netherland study [25], no age- and sex-related difference was identified in the association between UA and hypertension.

Therefore, to provide more evidence to solve the controversies, the aim of this study is to investigate the association between hyperuricemia and hypertension in a large Chinese population. Also, stratified analyses were conducted to further classify whether this association was gender- and age-specific.

2. Methods

2.1. Subjects and General Data Collection. This study is a large-scale, single-center, cross-sectional investigation in the Tianjin municipality of China. The database was from Tianjin Medical University General Hospital: UA, alanine aminotransferase (ALT), total bilirubin (TBIL), blood urea nitrogen (BUN), creatinine (Cr), total cholesterol (TC), triglycerides (TG), and fasting glucose (FG). The reference ranges for blood parameters were as follows: ALT 5–40 U/L, TBIL 3.4–20.0 μmol/L, BUN 1.7–8.3 mmol/L, Cr 44–115 μmol/L, TC 3.59–5.18 mmol/L, TG 0.57–1.70 mmol/L, and FG 3.6–5.8 mmol/L.

2.5. Definition. Increased systolic blood pressure (SBP) and increased diastolic blood pressure (DBP) were defined as ≥140 mmHg and ≥90 mmHg, respectively. And increased SBP and/or increased DBP was considered as hypertension in line with the US and European guidelines [35, 36]. Criteria for hyperuricemia were determined as >420 μmol/L in men and >360 μmol/L in women [7–9]. Age subgrouping for prevalence analysis was determined according to the following cutoffs: age ≤ 20 years, 20 years < age ≤ 30 years, 30 years < age ≤ 40 years, 40 years < age ≤ 50 years, 50 years < age ≤ 60 years, 60 years < age ≤ 70 years, and age > 70 years. And binary logistic regression was performed according to the following three age categories: young age (≤30 years), middle age (30 years < age ≤ 60 years), and old age (>60 years).

2.6. Statistical Analysis. Data were analyzed in males and females separately. Continuous variables including age, BMI, and clinical parameters were expressed as median (interquartile range (IQR)), since they were not consistent in normal distribution, and their differences between subjects with hypertension and those without hypertension were compared with the Mann-Whitney U test. Categorical data (prevalence) were expressed as percentages and numbers. The prevalence differences of hypertension and hyperuricemia between males and females were compared with the chi-square test, and the prevalence trend in relation to age group was analyzed with the Cochran-Armitage trend test. The multivariate logistic regression model was used to...
analyze the association between hyperuricemia and hypertension, and a variable selection procedure was based on the backward LR method. A two-sided $P$ value $< 0.05$ was considered as statistically significant. Statistical assessments were performed using the 3.71 release of SAS Studio for the 9.4M5 version of SAS (SAS Institute Inc., Cary, NC, USA) or IBM SPSS Statistics Version 17.0 software (International Business Machines Corp., Armonk, NY, USA).

3. Results

The prevalence of hypertension was significantly higher in males (30.04%) than in females (20.22%) (Table 1). When this comparison was stratified according to age group, the significant difference between males and females was observed in those aged 20-70 years. In addition, hypertension prevalence in both genders increased with age significantly.

The prevalence of hyperuricemia demonstrated a similar pattern of gender difference (Table 2). Also, with the increase in age, the prevalence of hyperuricemia significantly reduced in males while it significantly increased in females.

The basic clinical characteristics of participants with or without hypertension in males and females are summarized in Table 3. The median UA concentrations in male and female hypertensive participants were 365.0 μmol/L and 282.0 μmol/L, respectively, both significantly higher than those in men and women without hypertension. Similarly, age, BMI, and most other clinical parameters were higher in those with hypertension than in those with normotension in both genders, except for levels of TBIL and Cr in men and the TBIL level in women. In addition, the median UA concentrations in males were all higher than those in females whether with hypertension (354.0 μmol/L versus 253.0 μmol/L) or without hypertension (365.0 μmol/L versus 282.0 μmol/L), and the distribution of other parameters in Table 3 was significantly different between males and females.

We further analyzed the relationship between hyperuricemia and hypertension according to gender and age with multivariate logistic regression. And parameters which were significantly different between participants with and without hypertension were adjusted as covariates (Table 4). In males, hyperuricemia was an independent risk factor of hypertension with an adjusted OR of 1.131 (95% CI: 1.073-1.192). When this analysis was repeated according to age, the significant relationship between hyperuricemia and hypertension was only observed in those aged between 30 and 60. On the contrary, no significant relationship between hyperuricemia and hypertension was observed in females. Similarly, hyperuricemia was also an independent risk factor of increased SBP and DBP in males, but not in females, though results of stratified analysis suggested that hyperuricemia increased the risk of increased DBP significantly in females aged over 60. In order to validate our findings, we stratified our data according to the serum Cr level (in accordance with the lower reference range of 44 μmol/L and the upper reference range of 115 μmol/L). We found that the majority of the included cases were within the normal ranges of Cr (male 99.6% and female 98.4%); only 0.4% of men and 0.1% of women had a Cr level higher than 115 μmol/L (Supplementary Table 1). Then, the relationship between hyperuricemia and hypertension was analyzed according to various categories of Cr (Supplementary Tables 2, 3, and 4). We found the same phenomenon as discovered above. Men with hyperuricemia (particularly in middle age) had a significantly increased susceptibility of hypertension, while this significant association was not observed in women. There were too small numbers of cases with the Cr level higher than 115 μmol/L, especially in women, some analyses could not be performed (Supplementary Tables 1 and 4).

4. Discussion

The current study showed that gender and age had a significant impact on the association between hyperuricemia and hypertension in this Chinese population. We found that men with hyperuricemia (particularly in middle age) had a significantly increased susceptibility of hypertension, while no significant association was observed in women.

When exploring the possibility of hyperuricemia as a risk factor of hypertension, it is important to keep in mind the mechanisms of UA production and excretion. Although some mammals, like rats, have uricase (a UA-degrading enzyme), humans lost uricase during the course of evolution. Therefore, as the final metabolite of purine metabolism, UA tends to accumulate in the body, which indeed importantly constitutes the purine skeletons of nucleic acids, adenine, and guanine. There are two routes by which purine enters the human body, through either oral intake or biosynthesis; the latter provides a significantly higher amount of purine than the former. In terms of UA excretion, approximately two thirds occur in the kidney and one third in the digestive tract. Various factors are involved in the processes of UA production and secretion; any malfunction in these steps could lead to hyperuricemia [37].

The biological links between hyperuricemia and hypertension are not fully understood, but continue to be uncovered. There are several lines of evidence for pathomechanistic postulations. A high level of UA can cause arterial stiffness and endothelial dysfunction by two main mechanisms [38, 39]. In the urate crystal mechanism, serum UA itself directly causes arteriosclerosis. Macrophages can engulf the urate crystal, which causes the activation of the Nod-like receptor family protein 3 inflammasome. In the crystal-independent mechanism, the process of UA production by xanthine oxidoreductase is associated with oxidative stress [40], which reduces endothelial nitric oxide bioavailability and stimulates the intracellular renin-angiotensin system. Over time, this process will lead to irreversible vasoconstriction and remodeling in intrarenal vasculature [41]. In addition, the role of insulin resistance can also explain the relationship between UA and hypertension. Elevated insulin levels lead to low urinary ammonium levels and predispose to the precipitation of UA [42]. Insulin resistance acts via distinct and independent mechanisms and contributes to the development of metabolic disorders and hypertension. An in vivo and in vitro study demonstrated that a high serum UA level could directly induce insulin
| Gender   | All      | Age ≤ 20 | 20 < age ≤ 30 | 30 < age ≤ 40 | 40 < age ≤ 50 | 50 < age ≤ 60 | 60 < age ≤ 70 | Age > 70 | P trend |
|----------|----------|----------|--------------|--------------|--------------|--------------|--------------|----------|--------|
| Male     |          |          |              |              |              |              |              |          | <0.001 |
| Normotension | 69.96% (33429) | 98.21% (55) | 89.87% (4651) | 82.02% (8623) | 69.45% (10173) | 61.53% (7160) | 53.09% (2158) | 36.08% (609) |        |
| Hypertension | 30.04% (14352) | 1.79% (1) | 10.13% (524) | 17.98% (1890) | 30.55% (4475) | 38.47% (4476) | 46.91% (1907) | 63.92% (1079) | <0.001 |
| Female   |          |          |              |              |              |              |              |          | <0.001 |
| Normotension | 79.78% (24583) | 100.00% (25) | 98.24% (3512) | 96.14% (5924) | 87.84% (7187) | 71.39% (5625) | 50.52% (1763) | 36.42% (547) | <0.001 |
| Hypertension | 20.22% (6232) | 0.00% (0) | 1.76% (63) | 3.86% (238) | 12.16% (995) | 28.61% (2254) | 49.48% (1727) | 63.58% (955) |        |
| P value  | <0.001   | 0.501    | <0.001       | <0.001       | <0.001       | <0.001       | 0.026       | 0.842    |        |
### Table 2: Prevalence of hyperuricemia on different genders according to age.

| Gender   | All     | Age ≤ 20 | 20 < age ≤ 30 | 30 < age ≤ 40 | 40 < age ≤ 50 | 50 < age ≤ 60 | 60 < age ≤ 70 | Age > 70 | P trend |
|----------|---------|----------|---------------|---------------|---------------|---------------|---------------|----------|---------|
| Male     |         |          |               |               |               |               |               |          |         |
| Normotension | 79.90% (38177) | 52.50% (35) | 78.38% (4056) | 77.05% (8100) | 78.86% (11552) | 82.37% (9584) | 85.76% (3486) | 80.81% (1364) | <0.001  |
| Hypertension | 20.10% (9604)  | 37.50% (21) | 21.62% (1119) | 22.95% (2413) | 21.14% (3096) | 17.63% (2052) | 14.24% (579)  | 19.19% (324)  |         |
| Female   |         |          |               |               |               |               |               |          |         |
| Normotension | 93.68% (28867) | 100.00% (25) | 96.03% (3433) | 97.01% (5978) | 96.36% (7884) | 91.83% (7235) | 87.85% (3066) | 82.96% (1246) | <0.001  |
| Hypertension | 6.32% (1948)  | 0.00% (0)  | 3.97% (142)   | 2.99% (184)   | 3.64% (298)   | 8.17% (644)   | 12.15% (424)  | 17.04% (256)  |         |
| P value  | <0.001  | <0.001   | <0.001        | <0.001        | <0.001        | <0.001        | <0.001        | 0.007    | 0.116   |
Table 3: Comparisons of medians (IQR) of clinical parameters based on different genders.

| Parameters | Normotension | Male Hypertension | P value | Normotension | Female Hypertension | P value |
|------------|--------------|-------------------|---------|--------------|---------------------|---------|
| Age (years) | 44.0 (17.0)  | 51.0 (15.0)       | <0.001  | 44.00 (18.0) | 58.0 (15.0)         | <0.001  |
| BMI (kg/m²) | 25.3 (3.9)   | 26.8 (4.0)        | <0.001  | 23.1 (4.2)   | 26.0 (4.7)          | <0.001  |
| UA (μmol/L)| 354.0 (93.0) | 365.0 (99.0)      | <0.001  | 253.0 (72.0) | 282.0 (85.0)        | <0.001  |
| ALT (U/L)  | 22.0 (14.0)  | 24.0 (17.0)       | <0.001  | 15.0 (8.0)   | 18.0 (11.0)         | <0.001  |
| TBIL (μmol/L)| 12.8 (6.7)   | 12.8 (6.6)        | 0.742   | 10.4 (6.5)   | 10.4 (5.1)          | 0.107   |
| BUN (mmol/L)| 4.8 (1.6)    | 5.0 (1.7)         | <0.001  | 4.2 (1.5)    | 4.7 (1.6)           | <0.001  |
| Cr (μmol/L)| 79.0 (14.0)  | 79.0 (15.0)       | 0.162   | 59.0 (12.0)  | 60.0 (13.0)         | <0.001  |
| TC (mmol/L)| 5.0 (1.2)    | 5.22 (1.2)        | <0.001  | 5.0 (1.3)    | 5.59 (1.3)          | <0.001  |
| TG (mmol/L)| 1.4 (1.0)    | 1.64 (1.2)        | <0.001  | 0.97 (0.7)   | 1.44 (1.0)          | <0.001  |
| FG (mmol/L)| 5.0 (0.7)    | 5.3 (0.9)         | <0.001  | 4.8 (0.8)    | 5.2 (0.9)           | <0.001  |
| IQR: interquartile range; BMI: body mass index; UA: uric acid; ALT: alanine aminotransferase; TBIL: total bilirubin; BUN: blood urea nitrogen; Cr: creatinine; TC: total cholesterol; TG: triglycerides; FG: fasting glucose.

Table 4: High blood pressure associated with hyperuricemia in different age categories of men and women.

| Hypertension | Male | Female |
|--------------|------|--------|
|              | Crude OR (95% CI) | Adjusted OR (95% CI) | Crude OR (95% CI) | Adjusted OR (95% CI) |
| All participants | 1.387 (1.323-1.454)** | 1.131 (1.073-1.192)** | 3.242 (2.662-3.949)** | 0.797 (0.606-1.050) |
| Age ≤ 30 (years) | 2.036 (1.677-2.471)** | 1.214 (0.980-1.502)  | 8.792 (2.544-30.38)  | 2.827 (0.739-10.810)
| 30 < age ≤ 60 (years) | 1.485 (1.408-1.566)** | 1.121 (1.058-1.188)** | 2.761 (2.066-3.689)** | 0.804 (0.554-1.168) |
| Age > 60 (years) | 1.238 (1.073-1.428)** | 0.935 (0.772-1.132)  | 1.397 (1.026-1.901)** | 0.948 (0.684-1.314) |
| Increased SBP | 1.257 (1.190-1.327)** | 1.085 (1.021-1.153)** | 3.472 (2.845-4.237)** | 0.803 (0.605-1.065) |
| Age ≤ 30 (years) | 2.304 (1.823-2.912)** | 1.355 (1.051-1.747)* | 5.561 (0.725-42.64)  | 1.208 (0.145-10.066)
| 30 < age ≤ 60 (years) | 1.359 (1.275-1.449)** | 1.044 (0.975-1.119)  | 3.061 (2.684-3.131)** | 0.867 (0.588-1.179) |
| Age > 60 (years) | 1.242 (1.078-1.432)** | 0.930 (0.769-1.125)  | 1.143 (1.062-1.960)* | 0.953 (0.688-1.320) |
| Increased DBP | 1.453 (1.383-1.526)** | 1.102 (1.030-1.179)** | 2.568 (2.037-3.237)** | 1.119 (0.877-1.427) |
| Age ≤ 30 (years) | 1.974 (1.594-2.446)** | 1.141 (0.905-1.438)  | 7.153 (1.630-31.38)  | 1.931 (0.233-16.003)
| 30 < age ≤ 60 (years) | 1.527 (1.446-1.613)** | 1.152 (1.086-1.222)** | 2.233 (1.592-3.132)** | 0.912 (0.638-1.303) |
| Age > 60 (years) | 1.119 (0.962-1.303) | 0.947 (0.808-1.110)  | 1.746 (1.251-2.437)** | 1.519 (1.077-2.143)*

OR: odds ratio; CI: confidence interval; SBP: systolic blood pressure; DBP: diastolic blood pressure. * Adjusted for age, BMI, ALT, BUN, Cr, TC, and FG. ** Adjusted for age, BMI, ALT, BUN, Cr, TC, TG, and FG. P < 0.05 and **P < 0.01.

resistance by inhibiting IRS1 and Akt insulin signaling [43]. In this way, the relationship between hyperuricemia and risks of hypertension in our findings can be comprehended from the molecular explanations.

Hyperuricemia appears to have a stronger impact on the susceptibility to develop hypertension in men than in women, especially in middle-aged males. We try to explain this in the following points. Firstly, sex hormones play a central role in this phenomenon. Circulating UA levels in women are clearly lower than those in men (Table 3), which is putatively the result of the sex hormone in action. Estrogen in women increases renal urate clearance and lowers tubular urate postsecretory reabsorption [44]. Although sex hormone influence will subside in old-aged people after menopause, the serum UA level will be decreased after hormone replacement therapy in postmenopausal women with hyperuricemia [45]. Therefore, the current clinical data (Tables 1 and 2) could putatively reflect that estrogen could decrease the hyperuricemia prevalence in females, which could also suppress the hypertension prevalence in females. Secondly, it has been reported that in middle-aged men in particular, increasing insulin resistance and central obesity is well correlated with a rise in UA [18, 46]. Middle-aged men tend to have more unhealthy lifestyle risk factors that can increase UA, such as more alcohol consumption and less physical exercises [18, 46–48]. On the other hand, middle-aged women are more
prone to comply with the health practitioner’s advice about keeping fitness, while men tend to be more sedentary [49]. These lifestyle factors will deteriorate the susceptibility in men with hyperuricemia to develop hypertension (Table 4). Thirdly, differences in the expression of urate transporters in nonrenal tissues due to genetic variant SLC2A9 could also regulate blood pressure inhomogeneously in men and women [50]. Indeed, genotype and genetic polymorphism-related changes in the association between UA and blood pressure have also been proven in other laboratories [51, 52].

Interpretation of the present data could be limited by the following factors [1]. This is a cross-sectional, single-center study, which may have selection bias and lack of representativeness, and such a study cannot provide causality information [2]. Some subjects might have white-coat hypertension during the recruitment. Although ambulatory blood pressure monitoring is the best method, it is difficult to be implemented in the setting of an annual medical examination [3]. Serum parameters were measured only once. Sex hormone levels, oxidative stress, insulin resistance, endothelial function, and genotype or genetic polymorphism were not evaluated in the study; thus, their potential confounding effects could not be adjusted for [4]. This is an observational study; interventional studies are needed to clarify whether UA-lowering drugs are useful in preventing development of hypertension, which will validate the findings of the current investigation.

In conclusion, we showed significantly higher overall prevalence of hyperuricemia and hypertension in men than in women, and this difference was more prominent in the young and middle-aged population. Men with hyperuricemia (particularly in middle age) had a significantly increased susceptibility of having hypertension, while this significant association was not observed in women. Further prospective studies in different populations are warranted in investigating the gender- and age-specific association between hyperuricemia and hypertension.

Data Availability
The data used to support the findings of this study are available from the corresponding authors upon request.

Conflicts of Interest
We declare no conflict of interest in the paper.

Authors’ Contributions
Xiaoyun Lin, Xiqian Wang, and Xin Li as co-first authors contributed equally in the paper.

Acknowledgments
This study was supported by the National Key Clinical Specialty Project (awarded to the Departments of Nuclear Medicine and Radiology). This study was supported by the Tianjin Medical University General Hospital New Century Excellent Talent Program, the Young and Middle-Aged Innovative Talent Training Program from the Tianjin Education Committee, and the Talent Fostering Program (the 131 Project) from the Tianjin Education Committee and the Tianjin Human Resources and Social Security Bureau (to Zhaowei Meng). This study was also supported by the following grants: China National Natural Science Foundation grant #81571709 (to Zhaowei Meng), #81870533 (to Jinhong Sun), #71804124 (to Ying Gao), and #81872235 (to Li Zhao); Key Project of Tianjin Science and Technology Committee Foundation grant #16JCZDJC34300 (to Zhaowei Meng) and #15YYFSZY0020 (to Wenjuan Zhang); Tianjin Science and Technology Committee Foundation grant #17JCYBJC25400 (to Yaguang Fan), #15JCYBJC28000 (to Yongle Li), #11ZCGYSY05700 (to Qing Zhang), and #13ZCZDSY20200 (to Kun Song); Tianjin Education Committee grant #20110152 (to Xin Du); and Tianjin Health Bureau grant #2015KZ117 (to Xuefang Yu).

Supplementary Materials
The supplementary materials are provided in order to validate our findings, according to reviewers’ suggestions. We calculate our data according to the serum creatinine level (lower reference range 44 μmol/L and upper reference range 115 μmol/L). The relationship between hyperuricemia and hypertension is analyzed according to various categories of creatinine. We validate the same phenomenon that men with hyperuricemia (particularly in middle age) have a significantly increased susceptibility of hypertension, while this significant association is not observed in women. (Supplementary Materials)

References
[1] K. T. Mills, J. D. Bundy, T. N. Kelly et al., “Global disparities of hypertension prevalence and control: a systematic analysis of population-based studies from 90 countries,” Circulation, vol. 134, no. 6, pp. 441–450, 2016.
[2] B. Zhou, J. Bentham, M. di Cesare et al., “Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19.1 million participants,” The Lancet, vol. 389, no. 10064, pp. 37–55, 2017.
[3] K. L. Rock, H. Kataoka, and J. J. Lai, “Uric acid as a danger signal in gout and its comorbidities,” Nature Reviews Rheumatology, vol. 9, no. 1, pp. 13–23, 2013.
[4] G. Mule, E. Nardi, L. Lattuca, and S. Cottone, “Hyperuricemia and high blood pressure at rest and during exercise: guilty or innocent? The jury is still out,” Journal of Clinical Hypertension, vol. 20, no. 3, pp. 557–559, 2018.
[5] D. I. Feig, “Hyperuricemia and hypertension,” Advances in Chronic Kidney Disease, vol. 19, no. 6, pp. 377–385, 2012.
[6] M. Mazzali, J. Hughes, Y. G. Kim et al., “Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism,” Hypertension, vol. 38, no. 5, pp. 1101–1106, 2001.
[7] Q. Zhang, S. Lou, Z. Meng, and X. Ren, “Gender and age impacts on the correlations between hyperuricemia and metabolic syndrome in Chinese,” Clinical Rheumatology, vol. 30, no. 6, pp. 777–787, 2011.
[8] L. Liu, S. Lou, K. Xu, Z. Meng, Q. Zhang, and K. Song, “Relationship between lifestyle choices and hyperuricemia in Chinese men and women,” *Clinical Rheumatology*, vol. 32, no. 2, pp. 233–239, 2013.

[9] J. Zhang, Z. Meng, Q. Zhang et al., “Gender impact on the correlations between subclinical thyroid dysfunction and hyperuricemia in Chinese,” *Clinical Rheumatology*, vol. 35, no. 1, pp. 143–149, 2016.

[10] T. M. Palmer, B. G. Nordestgaard, M. Benn et al., “Association of plasma uric acid with ischaemic heart disease and blood pressure: Mendelian randomisation analysis of two large cohorts,” *BMJ*, vol. 347, no. jul18 1, p. 4262, 2013.

[11] L. Borgi, C. McMullan, A. Wohlhueter, G. C. Curhan, N. D. Fisher, and J. P. Forman, “Effect of uric acid-lowering agents on endothelial function: a randomized, double-blind, placebo-controlled trial,” *Hypertension*, vol. 69, no. 2, pp. 243–248, 2017.

[12] C. J. McMullan, L. Borgi, N. Fisher, G. Curhan, and J. Forman, “Effect of uric acid lowering on renin-angiotensin-system activation and ambulatory BP: a randomized controlled trial,” *Clinical Journal of the American Society of Nephrology*, vol. 12, no. 5, pp. 807–816, 2017.

[13] P. C. Grayson, S. Y. Kim, M. LaValley, and H. K. Choi, “Hyperuricemia and incident hypertension: a systematic review and meta-analysis,” *Arthritis Care & Research*, vol. 63, no. 1, pp. 102–110, 2011.

[14] M. Kuwabara, I. Hisatome, K. Niwa et al., “Uric acid is a strong risk marker for developing hypertension from prehypertension: a 5-year Japanese cohort study,” *Hypertension*, vol. 71, no. 1, pp. 78–86, 2018.

[15] S. Nishio, Y. Maruyama, N. Sugano, T. Hosoya, T. Yokoo, and S. Kuriyama, “Gender interaction of uric acid in the development of hypertension,” *Clinical and Experimental Hypertension*, vol. 40, no. 5, pp. 446–451, 2017.

[16] L. F. Loefller, A. Navas-Acien, T. M. Brady, E. R. Miller III, and J. J. Fadrowski, “Uric acid level and elevated blood pressure in US adolescents: National Health and Nutrition Examination Survey, 1999-2006,” *Hypertension*, vol. 59, no. 4, pp. 811–817, 2012.

[17] A. L. Gaffo, D. R. Jacobs Jr., F. Sijsma, C. E. Lewis, T. R. Mikuls, and K. G. Saag, “Serum urate association with hypertension in young adults: analysis from the Coronary Artery Risk Development in Young Adults cohort,” *Annals of the Rheumatic Diseases*, vol. 72, no. 8, pp. 1321–1327, 2013.

[18] S. F. Wang, L. Shu, S. Wang et al., “Gender difference in the association of hyperuricemia with hypertension in a middle-aged Chinese population,” *Blood Pressure*, vol. 23, no. 6, pp. 339–344, 2014.

[19] L. Wu, Y. He, B. Jiang et al., “Association between serum uric acid level and hypertension in a Chinese elderly rural population,” *Clinical and Experimental Hypertension*, vol. 39, no. 6, pp. 505–512, 2017.

[20] M. Kuwabara, K. Niwa, Y. Nishi et al., “Relationship between serum uric acid levels and hypertension among Japanese individuals not treated for hyperuricemia and hypertension,” *Hypertension Research*, vol. 37, no. 8, pp. 785–789, 2014.

[21] F. N. Yu, Y. X. Shi, H. Y. Cheng, X. L. Huang, and S. S. Liu, “An observational study on the relationship between serum uric acid and hypertension in a Northern Chinese population aged 45 to 59 years,” *Medicine*, vol. 96, no. 17, article e6773, 2017.

[22] J. J. Lee, J. Ahn, J. Hwang et al., “Relationship between uric acid and blood pressure in different age groups,” *Clinical Hypertension*, vol. 21, no. 1, p. 14, 2015.

[23] Y. Yokoi, T. Kondo, N. Okumura et al., “Serum uric acid as a predictor of future hypertension: stratified analysis based on body mass index and age,” *Preventive Medicine*, vol. 90, pp. 201–206, 2016.

[24] W. Cheng, S. Wen, Y. Wang et al., “The association between serum uric acid and blood pressure in different age groups in a healthy Chinese cohort,” *Medicine (Baltimore)*, vol. 96, no. 50, article e9853, 2017.

[25] L. E. J. M. Scheepers, A. Boonen, P. C. Dagnelie et al., “Uric acid and blood pressure: exploring the role of uric acid production in the Maastricht Study,” *Journal of Hypertension*, vol. 35, no. 10, pp. 1968–1975, 2017.

[26] Z. Meng, M. Liu, Q. Zhang et al., “Gender and age impacts on the association between thyroid function and metabolic syndrome in Chinese,” *Medicine*, vol. 94, no. 50, article e2193, 2015.

[27] Z. Meng, M. Liu, Q. Zhang et al., “Gender and age impact on the association between thyroid-stimulating hormone and serum lipids,” *Medicine*, vol. 94, no. 49, article e2186, 2015.

[28] X. Ren, Z. Meng, M. Liu et al., “No associations exist between mean platelet volume or platelet distribution width and thyroid function in Chinese,” *Medicine*, vol. 95, no. 40, article e4573, 2016.

[29] P. Zhou, Z. Meng, M. Liu et al., “The associations between leukocyte, erythrocyte or platelet, and metabolic syndrome in different genders of Chinese,” *Medicine*, vol. 95, no. 44, article e5189, 2016.

[30] S. Wang, J. Zhang, L. Zhu et al., “Association between liver function and metabolic syndrome in Chinese men and women,” *Scientific Reports*, vol. 7, no. 1, article 44844, 2017.

[31] X. Liu, C. Zhang, Z. Meng et al., “Waist circumference and subclinical thyroid dysfunction in a large cohort of Chinese men and women,” *Endocrine Practice*, vol. 24, no. 8, pp. 733–739, 2018.

[32] C. Zhang, Z. Meng, X. Li et al., “No associations exists between red blood cell distribution width and serum uric acid in both sexes,” *Medicine*, vol. 97, no. 40, article e2707, 2018.

[33] X. Zhang, Z. Meng, X. Li et al., “The association between total bilirubin and serum triglyceride in both sexes in Chinese,” *Lipids in Health and Disease*, vol. 17, no. 1, p. 217, 2018.

[34] F. Zhao, Z. Yan, Z. Meng et al., “Relationship between mean platelet volume and metabolic syndrome in Chinese patients,” *Scientific Reports*, vol. 8, no. 1, article 14574, 2018.

[35] A. V. Chobanian, G. L. Bakris, H. R. Black et al., “The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report,” *JAMA*, vol. 289, no. 19, pp. 2560–2572, 2003.

[36] G. Mancia, G. de Backer, A. Dominiczak et al., “2007 guidelines for the management of arterial hypertension,” *Journal of Hypertension*, vol. 25, no. 6, pp. 1105–1187, 2007.

[37] M. Kuwabara, “Hyperuricemia, cardiovascular disease, and hypertension,” *Pulse*, vol. 3, no. 3–4, pp. 242–252, 2016.

[38] M. Kuwabara, M. Kanbay, and I. Hisatome, “Uric acid and hypertension because of arterial stiffness,” *Hypertension*, vol. 72, no. 3, pp. 582–584, 2018.

[39] H. Tomiyama, K. Shiina, C. Vlachopoulos et al., “Involvement of arterial stiffness and inflammation in hyperuricemia-related
development of hypertension,” *Hypertension*, vol. 72, no. 3, pp. 739–745, 2018.

[40] B. Schmitz and S. M. Brand, “Uric acid and essential hypertension,” *Journal of Hypertension*, vol. 34, no. 11, pp. 2138–2139, 2016.

[41] C. Bavishi, F. H. Messerli, and S. F. Rimoldi, “Serum uric acid in primary hypertension: from innocent bystander to primum movens?,” *Hypertension*, vol. 67, no. 5, pp. 845–847, 2016.

[42] E. Bonora, B. Capaldo, P. C. Perin et al., “Hyperinsulinemia and insulin resistance are independently associated with plasma lipids, uric acid and blood pressure in non-diabetic subjects. The GISIR database,” *Nutrition, Metabolism, and Cardiovascular Diseases*, vol. 18, no. 9, pp. 624–631, 2008.

[43] Y. Zhu, Y. Hu, T. Huang et al., “High uric acid directly inhibits insulin signalling and induces insulin resistance,” *Biochemical and Biophysical Research Communications*, vol. 447, no. 4, pp. 707–714, 2014.

[44] F. Mateos Antón, J. García Puig, T. Ramos, P. González, and J. Ordás, “Sex differences in uric acid metabolism in adults: evidence for a lack of influence of estradiol-17β (E2) on the renal handling of urate,” *Metabolism*, vol. 35, no. 4, pp. 343–348, 1986.

[45] A. E. Hak and H. K. Choi, “Menopause, postmenopausal hormone use and serum uric acid levels in US women—the Third National Health and Nutrition Examination Survey,” *Arthritis Research & Therapy*, vol. 10, no. 5, p. R116, 2008.

[46] H. Y. Chang, W. H. Pan, W. T. Yeh, and K. S. Tsai, “Hyperuricemia and gout in Taiwan: results from the Nutritional and Health Survey in Taiwan (1993–96),” *The Journal of Rheumatology*, vol. 28, pp. 1640–1646, 2001.

[47] T. Ka, T. Yamamoto, Y. Moriwaki et al., “Effect of exercise and beer on the plasma concentration and urinary excretion of purine bases,” *The Journal of Rheumatology*, vol. 30, no. 5, pp. 1036–1042, 2003.

[48] M. Krzystek-Korpacka, E. Patryn, I. Kustrzeba-Wojcicka, J. Chrzanowska, A. Gamian, and A. Noczynska, “The effect of a one-year weight reduction program on serum uric acid in overweight/obese children and adolescents,” *Clinical Chemistry and Laboratory Medicine*, vol. 49, no. 5, pp. 915–921, 2011.

[49] S.-A. Lee, W. H. Xu, W. Zheng et al., “Physical activity patterns and their correlates among Chinese men in Shanghai,” *Medicine and Science in Sports and Exercise*, vol. 39, no. 10, pp. 1700–1707, 2007.

[50] A. Doring, C. Gieger, D. Mehta et al., “SLC2A9 influences uric acid concentrations with pronounced sex-specific effects,” *Nature Genetics*, vol. 40, no. 4, pp. 430–436, 2008.

[51] T. K. Yeh, T. C. Yeh, C. F. Weng et al., “Association of polymorphisms in genes involved in the dopaminergic pathway with blood pressure and uric acid levels in Chinese females,” *Journal of Neural Transmission*, vol. 117, no. 12, pp. 1371–1376, 2010.

[52] A. Parsa, E. Brown, M. R. Weir et al., “Genotype-based changes in serum uric acid affect blood pressure,” *Kidney International*, vol. 81, no. 5, pp. 502–507, 2012.